Atrin Pharmaceuticals
Small molecule ATR kinase inhibitors for cancer treatment
- Sector
- Biotech
- Headquarters
- DOYLESTOWN, PA
- Latest Form D
- $1.2M, Apr 2016
- Total capital
- $1.5M
- Federal grants
- $300K
- 1 award · 2016
- Rank in peer group#45 of 392
- Private capital raised
- $1.2M
- 1 Form D · last Apr 2016
- 127 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 5 pending · first 2017
- Rank in peer group#35 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers$300K
- Private capital raisedForm D · SEC · 1st filing$1.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#45 · top 11%
- Granted patents#35 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bernard C. RudnickExecutive Officer, DirectorNamed in SEC Form D filings
- Oren GiladExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 9- GrantedAtaxia Telengiectasia And RAD3-RELATED (atr) Inhibitors And Methods Of Their UseUSPTOUS 10,301,324
- GrantedAtaxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsUSPTOUS 10,196,405
- GrantedAtaxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsUSPTOUS 9,981,989
Show all 9 patent records
- Ataxia Telengiectasia And RAD3-RELATED (atr) Inhibitors And Methods Of Their UseMay 28, 2019 · US 10,301,324Granted
- Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsFeb 5, 2019 · US 10,196,405Granted
- Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsMay 29, 2018 · US 9,981,989Granted
- Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsMay 30, 2017 · US 9,663,535Granted
- Atr InhibitorsApplication 63330944Pending
- Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase InhibitorsApplication 62104274Pending
- Pharmaceutical Compositions And MethodsApplication 63196744Pending
- Ataxia Telengiectasia And RAD3-RELATED (atr) Inhibitors And Methods Of Their UseApplication PCTUS2017027172Pending
- Ataxia Telengiectasia And RAD3-RELATED (atr) Protein Kinase InhibitorsApplication PCTUS2015055317Pending
Related companies, and why
- ORPRO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- BIOLYTX PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
- ALLOSTEROS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- PANTHERICS INCORPORATEDSimilar federal contract value in Biotech · null in contracts
- MITOTHERAPEUTIX, LLCSimilar federal contract value in Biotech · null in contracts
- VIVACELLE BIO INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .